Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Studie av INBRX-106 og INBRX-106 i kombinasjon med Pembrolizumab hos personer med lokalt avanserte eller metastatiske solide svulster (heksavalent OX40-agonist)

4. november 2026 oppdatert av: Inhibrx Biosciences, Inc

En åpen, multisenter, første-i-menneske, dose-eskalering, fase 1-studie av INBRX-106 og INBRX-106 i kombinasjon med Pembrolizumab hos personer med lokalt avanserte eller metastatiske solide svulster

This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizumab (Keytruda®). KEYTRUDA is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

Studieoversikt

Studietype

Intervensjonell

Registrering (Antatt)

340

Fase

  • Fase 2
  • Fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • California
      • Duarte, California, Forente stater, 91010
        • Aktiv, ikke rekrutterende
        • City of Hope
      • Glendale, California, Forente stater, 91204
        • Rekruttering
        • Oncura Health
        • Ta kontakt med:
        • Hovedetterforsker:
          • Sungwon Kyung, MD
      • La Jolla, California, Forente stater, 92037
        • Har ikke rekruttert ennå
        • UC San Diego Health - Moores Cancer Center
        • Hovedetterforsker:
          • Lyudmila Bazhenova, MD
      • Los Angeles, California, Forente stater, 90027
        • Rekruttering
        • California Research Institute
        • Hovedetterforsker:
          • Ghassan Al-Jazayrly, MD
        • Ta kontakt med:
      • Los Angeles, California, Forente stater, 90069
      • Los Angeles, California, Forente stater, 90033
        • Har ikke rekruttert ennå
        • University of Southern California Norris Comprehensive Cancer Center
        • Hovedetterforsker:
          • Jorge Nieva, MD
      • Murrieta, California, Forente stater, 92562
        • Rekruttering
        • Valkyrie Clinical Trials
        • Hovedetterforsker:
          • David Berz, MD
        • Ta kontakt med:
      • Santa Rosa, California, Forente stater, 95403
        • Rekruttering
        • Providence Medical Foundation
        • Hovedetterforsker:
          • Ian Anderson, MD
        • Ta kontakt med:
    • Colorado
      • Lakewood, Colorado, Forente stater, 80228
        • Har ikke rekruttert ennå
        • Valkyrie Clinical Trials - Colorado
        • Hovedetterforsker:
          • Jason Henry, MD
    • Florida
      • Clermont, Florida, Forente stater, 34711
        • Rekruttering
        • Clermont Oncology Center
        • Hovedetterforsker:
          • Gopal Kunta, MD
        • Ta kontakt med:
      • Orange City, Florida, Forente stater, 32763
        • Rekruttering
        • Mid Florida Hematology and Oncology Center
        • Hovedetterforsker:
          • Santosh Nair, MD
        • Ta kontakt med:
    • Georgia
      • Atlanta, Georgia, Forente stater, 30322
        • Aktiv, ikke rekrutterende
        • Winship Cancer Institute - Emory University
    • Illinois
      • Chicago, Illinois, Forente stater, 60612
        • Har ikke rekruttert ennå
        • University of Illinois Cancer Center
        • Hovedetterforsker:
          • Frank Weinberg, MD, PhD
      • Chicago, Illinois, Forente stater, 60637
        • Aktiv, ikke rekrutterende
        • The University of Chicago Medical Center
    • Iowa
      • Iowa City, Iowa, Forente stater, 52242
        • Rekruttering
        • University of Iowa
        • Hovedetterforsker:
          • Douglas Laux, MD
        • Ta kontakt med:
    • Kentucky
      • Louisville, Kentucky, Forente stater, 40202
    • Michigan
      • Detroit, Michigan, Forente stater, 48202
        • Rekruttering
        • Henry Ford Cancer Institute
        • Hovedetterforsker:
          • Amy Weise, MD
        • Ta kontakt med:
      • Detroit, Michigan, Forente stater, 48201
        • Fullført
        • Barbara Ann Karmanos Cancer Institute
      • Grand Rapids, Michigan, Forente stater, 49546
        • Aktiv, ikke rekrutterende
        • START Midwest
    • Minnesota
      • Saint Louis Park, Minnesota, Forente stater, 55426
        • Aktiv, ikke rekrutterende
        • HealthPartners Cancer Research Center
      • Saint Paul, Minnesota, Forente stater, 55101
        • Fullført
        • HealthPartners Cancer Research Center (Regions Hospital)
    • Missouri
      • St Louis, Missouri, Forente stater, 63110
        • Har ikke rekruttert ennå
        • Washington University in St. Louis School of Medicine
        • Hovedetterforsker:
          • Brett Herzog, MD, PhD
    • Montana
      • Billings, Montana, Forente stater, 59102
        • Fullført
        • Intermountain Health Cancer Centers of Montana
    • Nebraska
      • Grand Island, Nebraska, Forente stater, 68803
        • Har ikke rekruttert ennå
        • Nebraska Cancer Specialists - Grand Island
        • Hovedetterforsker:
          • Ralph Hauke, MD
      • Omaha, Nebraska, Forente stater, 68130
        • Rekruttering
        • Nebraska Cancer Specialists
        • Hovedetterforsker:
          • Ralph Hauke, MD
        • Ta kontakt med:
    • New Jersey
      • Camden, New Jersey, Forente stater, 08103
        • Har ikke rekruttert ennå
        • MD Anderson Cancer Center at Cooper
        • Hovedetterforsker:
          • Polina Khrizman, MD
    • New York
      • The Bronx, New York, Forente stater, 10467
        • Aktiv, ikke rekrutterende
        • Montefiore Medical Center
    • Ohio
      • Cleveland, Ohio, Forente stater, 44195
        • Aktiv, ikke rekrutterende
        • Cleveland Clinic
    • Oregon
      • Portland, Oregon, Forente stater, 97213
        • Aktiv, ikke rekrutterende
        • Providence Portland Medical Center
    • Pennsylvania
      • Allentown, Pennsylvania, Forente stater, 18103
        • Har ikke rekruttert ennå
        • Lehigh Valley Health Network
        • Hovedetterforsker:
          • Muhammad Rizvi, MD
    • Tennessee
      • Knoxville, Tennessee, Forente stater, 37923
        • Har ikke rekruttert ennå
        • University of Tennessee Health Science Center
        • Hovedetterforsker:
          • Sean Jordan, MD
      • Nashville, Tennessee, Forente stater, 37204
        • Aktiv, ikke rekrutterende
        • Vanderbilt University School of Medicine
    • Texas
      • Dallas, Texas, Forente stater, 75230
        • Fullført
        • Sarah Cannon Research Institute at Mary Crowley
      • El Paso, Texas, Forente stater, 79915
        • Fullført
        • Renovatio Clinical - El Paso
      • San Antonio, Texas, Forente stater, 78229
        • Fullført
        • NEXT Oncology
      • The Woodlands, Texas, Forente stater, 77380
        • Fullført
        • Renovatio Clinical
      • Tyler, Texas, Forente stater, 75701
        • Rekruttering
        • The University of Texas Health Science Center at Tyler
        • Ta kontakt med:
        • Hovedetterforsker:
          • Erminia Massarelli, MD, PhD, MS
    • Virginia
      • Fairfax, Virginia, Forente stater, 22031
        • Fullført
        • Virginia Cancer Specialists
    • Wisconsin
      • Milwaukee, Wisconsin, Forente stater, 53226
        • Rekruttering
        • Froedtert Hospital and the Medical College of Wisconsin
        • Hovedetterforsker:
          • Jonathan Thompson, MD
        • Ta kontakt med:
      • Singapore, Singapore
        • Fullført
        • Curie Oncology
      • Singapore, Singapore
        • Fullført
        • Icon Cancer Centre Farrer Park
      • Singapore, Singapore
        • Fullført
        • Icon Cancer Centre Mount Alvernia
      • Busan, Sør -Korea
        • Har ikke rekruttert ennå
        • Inje University College of Medicine
        • Hovedetterforsker:
          • IL-Hwan Kim, MD, PhD
      • Cheongju-si, Sør -Korea
        • Har ikke rekruttert ennå
        • Chungbuk National University Hospital
        • Hovedetterforsker:
          • Ki-Hyeong Lee, MD
      • Gyeonggi-do, Sør -Korea
        • Rekruttering
        • The Catholic University of Korea, St. Vincent's Hospital
        • Hovedetterforsker:
          • Byoung Yong Shim
      • Hwasun, Sør -Korea
        • Har ikke rekruttert ennå
        • Chonnam National University Hwasun Hospital
        • Hovedetterforsker:
          • In-Jae Oh, MD, MS, PhD
      • Incheon, Sør -Korea
        • Har ikke rekruttert ennå
        • Gachon University Gil Medical Center
        • Hovedetterforsker:
          • Eun Kyung Cho, PhD, M.S
      • Seongnam-si, Sør -Korea
        • Har ikke rekruttert ennå
        • CHA Bundang Medical Center
        • Hovedetterforsker:
          • Yoon Beom Sang
      • Seoul, Sør -Korea
        • Rekruttering
        • Asan Medical Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Dae Ho Lee, MD
      • Seoul, Sør -Korea
        • Rekruttering
        • Severance Hospital, Yonsei University Health System
        • Ta kontakt med:
        • Hovedetterforsker:
          • Sun Mun Lim
      • Seoul, Sør -Korea
        • Rekruttering
        • The Catholic University of Korea Seoul St. Mary's Hospital,
        • Hovedetterforsker:
          • SookHee Hong
        • Ta kontakt med:
      • Seoul, Sør -Korea
        • Har ikke rekruttert ennå
        • Korea University Anam Hospital
        • Hovedetterforsker:
          • Yoon Ji Choi, MD, MS, PhD
      • Seoul, Sør -Korea
        • Har ikke rekruttert ennå
        • Hanyang University Seoul Hospital
        • Hovedetterforsker:
          • Myung- Ju Ahn, MD, PhD, MS
      • Seoul, Sør -Korea
        • Har ikke rekruttert ennå
        • Korea University Guro Hospital
        • Hovedetterforsker:
          • Sung Yong Lee
        • Hovedetterforsker:
          • Sung Yong Lee, MD, MS, PhD
      • Suwon, Sør -Korea
        • Har ikke rekruttert ennå
        • Ajou University Hospital
        • Hovedetterforsker:
          • Yong-Won Choi, MD
      • Changhua, Taiwan
        • Aktiv, ikke rekrutterende
        • Changhua Christian Hospital (CCH)
      • Kaohsiung City, Taiwan
        • Aktiv, ikke rekrutterende
        • E-Da Cancer Hospital
      • Kaohsiung City, Taiwan
        • Aktiv, ikke rekrutterende
        • Kaohsiung Medical University Chung-Ho Memorial Hospital (KMUH)
      • Tainan, Taiwan
        • Aktiv, ikke rekrutterende
        • National Cheng Kung University Hospital
      • Taipei, Taiwan
        • Fullført
        • Taipei Veterans General Hospital

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Select Inclusion Criteria:

  • Males or females aged ≥18 years.
  • Parts 1 and 3 (escalation cohorts): Subjects with locally advanced or metastatic non resectable solid tumors, whose disease has progressed despite all standard therapies or for whom no further standard or clinically acceptable therapy exists.
  • Part 2 (single-agent expansion cohort): Subjects with NSCLC, melanoma, HNSCC, G/GEA, RCC, or TCC, with histologically confirmed, locally advanced or metastatic, non-resectable disease, which has progressed despite all standard therapies including CPI or for whom no standard or clinically acceptable therapy exists.
  • Part 4 (expansion cohorts in combination with pembrolizumab, with or without chemotherapy): Subjects with melanoma (all types), HNSCC, G/GEA, RCC, TCC, NSCLC, or MSI-high, TMB-high, MMR-deficient tumors, with histologically confirmed, locally advanced or metastatic, non resectable disease, which is either CPI-naive (melanoma, HNSCC, NPC) or progressed despite all standard therapies including CPI (NSCLC, RCC, TCC, uveal melanoma, MSI-high, TMB-high, or MMR-deficient solid tumors) or for whom no standard or clinically acceptable therapy exists.
  • For Cohort F3 (NSCLC), subjects may have progressed on no more than 2 lines of standard therapy that must include at least one PD-1/L1 regimen.
  • For Cohort F4 (HNSCC and NPC), subjects may be previously treated with no more than 1 prior chemotherapy regimen in metastatic setting. Prior PD-1/L1 in curative (neo-adjuvant/adjuvant) setting is allowed only if completed >/= 6 months prior to progression to local recurrence or metastatic disease.
  • For Cohort F8, subjects must have previously untreated, histologically confirmed Stage II, IIIA or IIIB (T3-4N2) NSCLC. Lymph node disease requires histologic confirmation, while T3 disease requires only radiographic documentation. Subjects need to be able to undergo planned surgery.
  • All subjects with non-squamous NSCLC must have documentation of absence of tumor activating EGFR mutations and absence of ALK gene rearrangements.
  • PD-L1 by IHC (22C3): Parts 1 and 3: IHC optional. Part 2: IHC result mandatory but any score allowed. Combined Positive Score (CPS) ≥ 1% (or Tumor Proportion Score ≥50% for NSCLC; for TMB-high tumors, any TPS% is allowed). Part 4: Combined Positive Score (CPS) ≥ 1% (or Tumor Proportion Score ≥50% for NSCLC; for TMB-high tumors, any TPS% is allowed). For Cohort F8, any TPS (including 0%) is acceptable.
  • Adequate hematologic, coagulation, hepatic and renal function and ECOG score as defined per protocol.

Select Exclusion Criteria:

  • Prior exposure to OX40 agonists. Exposure to anti-PD-1 and/or anti PD-L2 CPIs or an agent targeting other co-stimulatory T-cell receptor pathways.
  • Receipt of any investigational product or any approved anticancer drug(s) or biological product(s) within 4 weeks prior to the first dose of study drug with certain exceptions.
  • Hematologic malignancies (e.g., ALL, AML, MDS, CLL, CML, NHL, Hodgkin's lymphoma and multiple myeloma)
  • Prior or concurrent malignancies. Exception: Subjects with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessments of INBRX-106.
  • Grade ≥ 3 immune-related adverse events (irAEs) or irAE that lead to discontinuation of prior immunotherapy. Some exceptions as defined per protocol apply.
  • Active autoimmune disease or documented history of autoimmune disease that required systemic steroids or other immunosuppressive medications. Certain exceptions as defined in protocol apply.
  • Diagnosis of immunodeficiency or treatment with systemic immunosuppressive medications within 7 days prior to the first dose of study drug. Certain exceptions as defined in protocol apply.
  • History of hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infection. Exceptions as defined in protocol apply.
  • Active interstitial lung disease (ILD) or pneumonitis or a history of ILD or pneumonitis requiring treatment with steroids or other immunosuppressive medications.
  • Clinically significant cardiac condition, including myocardial infarction, uncontrolled angina, viral myocarditis, cerebrovascular accident, or other acute uncontrolled heart disease < 3 months prior to enrollment on this trial; left ventricular ejection fraction (LVEF) < 50%; New York Heart Association (NYHA) Class III or IV congestive heart failure; or uncontrolled hypertension; or oxygen saturation <92% on room air.
  • Active, hemodynamically significant pulmonary embolism within 12 weeks prior to enrollment on this trial.
  • Major surgery within 4 weeks prior to enrollment on this trial.
  • Anti-infectious drug treatments (i.e., antibiotics) within 4 weeks prior to the first dose of study drug.
  • Prior organ allograft transplantations or allogeneic peripheral blood stem cell (PBSC) or bone marrow (BM) transplantation.
  • Additional in- and exclusion criteria per protocol.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Sekvensiell tildeling
  • Masking: Enkelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Part 1 INBRX-106 Escalation (Not Recruiting)

INBRX-106 will be escalated in subjects with locally advanced or metastatic solid tumors.

The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4).

Eksperimentell: Part 3 INBRX-106 Escalation in Combination with pembrolizumab (Not Recruiting)

INBRX-106 will be escalated, in combination with pembrolizumab, in subjects with locally advanced or metastatic solid tumors.

The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4).

pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.

Andre navn:
  • KEYTRUDA
Eksperimentell: Part 2 (Cohorts C1/C2) INBRX-106 Escalation in Various Solid Tumor Types (Not Recruiting)

Subjects with melanoma (any type), head and neck squamous cell carcinoma, renal cell carcinoma, urothelial carcinoma or MSI/TMB-high tumors that are relapsed or refractory to prior checkpoint inhibitor (CPI) therapy will be treated with INBRX-106

The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4).

pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.

Andre navn:
  • KEYTRUDA
Eksperimentell: Part 2 (Cohort C3) INBRX-106 Escalation in NSCLC (Not Recruiting)

Subjects with non-small cell carcinoma relapsed or refractory to prior checkpoint inhibitor (CPI) therapy will be treated with INBRX-106

pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.

Andre navn:
  • KEYTRUDA
Eksperimentell: Part 4 (Cohort F3a) INBRX-106 Expansion in Combination with pembrolizumab in NSCLC (Not Recruiting)

Subjects with non-small cell lung cancer will be treated with alternating dosing of INBRX-106 0.3 mg/kg Q6W and 400 mg pembrolizumab IV Q6W. This is one of the randomized cohorts.

The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4).

pembrolizumab 400 mg by IV infusion given on Day 1 of alternating 21-day cycles (every 6 weeks)

Andre navn:
  • KEYTRUDA
Eksperimentell: Part 4 (Cohort F3b) INBRX-106 Expansion in Combination with pembrolizumab in NSCLC (Not Recruiting)

Subjects with non-small cell lung cancer will be given a 0.3 mg/kg priming dose of INBRX-106 in cycle 1, followed by 0.1 mg/kg INBRX-106 and 200 mg pembrolizumab IV every 3 weeks in subsequent cycles. This is one of the randomized cohorts.

The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4).

pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.

Andre navn:
  • KEYTRUDA

pembrolizumab 400 mg by IV infusion given on Day 1 of alternating 21-day cycles (every 6 weeks)

Andre navn:
  • KEYTRUDA
Aktiv komparator: Part 4 (Cohort F3c) Pembrolizumab Expansion Arm (Not Recruiting)

Subjects with non-small cell lung cancer will be treated with 200 mg pembrolizumab IV every 3 weeks. This is one of the randomized cohorts.

The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4).

Eksperimentell: Part 4 (Cohort F3d) INBRX-106 Expansion in Combination with pembrolizumab in NSCLC (Not-Recruiting)

Subjects with non-small cell lung cancer will be treated concurrently every 6 weeks with INBRX-106 0.1 mg/kg and 200 mg pembrolizumab IV every 3 weeks. This is one of the randomized cohorts.

The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4).

Eksperimentell: Part 4 (Cohort F4) INBRX-106 Expansion in Combination with pembrolizumab (Not Recruiting)

Subjects with melanoma (any type), head and neck squamous cell carcinoma (non-nasopharyngeal) OR nasopharyngeal carcinoma, MSI-high, TMB-high or MMR-deficient tumors, will be treated with INBRX-106 in combination with 200mg pembrolizumab IV every 3 weeks.

The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4).

pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.

Andre navn:
  • KEYTRUDA
Eksperimentell: Part 4 (Cohort F5)INBRX-106 Expansion with pembrolizumab in MSI/TMB-high/MMRd tumors Not Recuriting

Subjects with solid tumors that have confirmed MSI-high, TMB-high or MMR-deficient states who are relapsed or refractory to checkpoint inhibitor (CPI) therapy will be treated with INBRX-106 and 200 mg pembrolizumab IV every 3 weeks

The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4).

pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.

Andre navn:
  • KEYTRUDA
Eksperimentell: Part 4 (Cohort F6) INBRX-106 Expansion with pembrolizumab in Uveal Melanoma (Not Recruiting)

Subjects with ocular (uveal) melanoma who are relapsed or refractory to checkpoint inhibitor (CPI) therapy will be treated with INBRX-106 and 200 mg pembrolizumab IV every 3 weeks

The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4).

pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.

Andre navn:
  • KEYTRUDA

carboplatin AUC-5 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4. Cohort F8, carboplatin AUC-5 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycle 2-4.

pemetrexed 500 mg/m2 by IV infusion given on Day 1 of each 21-Day cycle for up to 35 cycles. In Cohort F8, pemetrexed 500 mg/m2 by IV infusion given on Day 1 of each 21-Day cycle of cycles 1-4.

Andre navn:
  • Alimta®
Eksperimentell: Part 4 (Cohort F7a) INBRX-106 Expansion with pembrolizumab, pemetrexed and carboplatin in NSCLC

This Arm is no longer recruiting. Subjects with advanced/metastatic NSCLC, any PD-L1 TPS will be treated with INBRX-106 0.1mg/kg, 200mg pembrolizumab, 500mg/m2 pemetrexed and carboplatin AUC-5 IV every 3 weeks

The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4).

pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.

Andre navn:
  • KEYTRUDA

pemetrexed 500 mg/m2 by IV infusion given on Day 1 of each 21-Day cycle for up to 35 cycles. In Cohort F8, pemetrexed 500 mg/m2 by IV infusion given on Day 1 of each 21-Day cycle of cycles 1-4.

Andre navn:
  • Alimta®

cisplatin 75mg/m2 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4

Eksperimentell: Part 4 (Cohort F7b) INBRX-106 Expansion with pembrolizumab, pemetrexed and cisplatin in NSCLC

This Arm is no longer recruiting. Subjects with advanced/metastatic NSCLC, any PD-L1 TPS will be treated with INBRX-106 0.1mg/kg, 200mg pembrolizumab, 500mg/m2 pemetrexed and 75mg/m2 cisplatin IV every 3 weeks

The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4).

pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.

Andre navn:
  • KEYTRUDA

carboplatin AUC-6 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4

paclitaxel 200mg/m2 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4

Nab paclitaxel 100mg/m2 by intravenous (IV) infusion, given on Days 1, 8 and 15 of each 21-day cycle of cycles 1-4

Eksperimentell: Part 4(Cohort F7c)INBRX-106 Expansion with pembrolizumab, (Nab)-paclitaxel and carboplatin in NSCLC

This Arm is no longer recruiting. Subjects with advanced/metastatic NSCLC, any PD-L1 TPS will be treated with INBRX-106 0.1mg/kg, 200mg pembrolizumab, 200mg/m2 paclitaxel and carboplatin AUC-6 IV every 3 weeks OR INBRX-106, 200mg pembrolizumab, 100mg/m2 nab-paclitaxel (dosed Days 1,8 and 15 every cycle) and carboplatin AUC-6 IV every 3 weeks. Treating physician to determine if paclitaxel or nab-paclitaxel will be given

The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4).

pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.

Andre navn:
  • KEYTRUDA
Eksperimentell: Part 4(Cohort F8)INBRX-106 with pembrolizumab, cisplatin and gemcitabine or pemetrexed in NSCLC

Subjects with resectable Stage II, IIIA or IIIB (T3-4N2) NSCLC , any PD-L1 TPS will receive neoadjuvant treatment with INBRX-106 0.1 mg/kg, 200 mg pembrolizumab, cisplatin 75 mg/m2 (dosed Day 1 only) with gemcitabine 1000 mg/m2 (dosed on Days 1 and 8) for patients with squamous cell NSCLC given every 3 weeks OR neoadjuvant treatment with INBRX-106 0.1 mg/kg, 200 mg pembrolizumab, cisplatin 75 mg/m2 with pemetrexed 500 mg/m2 for patients with non-squamous cell NSCLC given every 3 weeks. Carboplatin AUC5 (dosed on Day 1 only) can be substituted for Cisplatin for subjects who are clinically considered ineligible or unsuitable for cisplatin per the Investigator's discretion or institution SOPs. Neoadjuvant treatment will be given for up to 4 cycles followed by surgery (lobectomy, bilobectomy or pneumonectomy). After surgery, all patients will receive adjuvant treatment consisting of INBRX-106 0.1 mg/kg, 200 mg pembrolizumab given every 3 weeks for up to 13 cycles.

The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4).

pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.

Andre navn:
  • KEYTRUDA

carboplatin AUC-5 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4. Cohort F8, carboplatin AUC-5 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycle 2-4.

pemetrexed 500 mg/m2 by IV infusion given on Day 1 of each 21-Day cycle for up to 35 cycles. In Cohort F8, pemetrexed 500 mg/m2 by IV infusion given on Day 1 of each 21-Day cycle of cycles 1-4.

Andre navn:
  • Alimta®

cisplatin 75mg/m2 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4

Gemcitabine 1000 mg/m2 given by intravenous (IV) infusion on Days 1 and 8 of each 21-day cycle of cycles 1-4

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Frequency of adverse events of INBRX-106 as single agent and in combination with pembrolizumab
Tidsramme: ~2 years

Adverse events will be assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0

~2 years
Severity of adverse events of INBRX-106 as single agent and in combination with pembrolizumab
Tidsramme: ~2 years

Adverse events will be assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0

~2 years
MTD and/or RP2D of INBRX-106 as single agent and in combination with pembrolizumab
Tidsramme: ~2 years

Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of INBRX-106 and INBRX-106 in combination with pembrolizumab

~2 years
Antitumor activity of INBRX-106 in combination with pembrolizumab in expansion cohorts
Tidsramme: ~2 years

The evaluation of efficacy will be based on the subject's measurable disease using RECIST v1.1

~2 years
Frequency and severity of adverse events of INBRX-106 in combination with pembrolizumab and chemotherapy in adults with locally advanced or metastatic NSCLC or resectable Stage II, IIIA or IIIB (T3-4N2) NSCLC
Tidsramme: ~2 years

Adverse events will be assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0

~2 years
To assess the antitumor activity of INBRX-106 in combination with pembrolizumab and platinum doublet chemotherapy as neoadjuvant/adjuvant therapy in adult subjects with NSCLC. (Cohort F8)
Tidsramme: ~2 years

Major pathological response (mPR) and pathological complete response (cPR) criteria.

~2 years

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Area under the serum concentration time curve (AUC) of INBRX-106
Tidsramme: ~2 years

Area under the serum concentration time curve (AUC) of INBRX-106 as a single agent and in combination with pembrolizumab with or without chemotherapy will be determined.

~2 years
Maximum observed serum concentration (Cmax) of INBRX-106
Tidsramme: ~2 years

Maximum observed serum concentration (Cmax) of INBRX-106 as a single agent and in combination with pembrolizumab with or without chemotherapy will be determined.

~2 years
Trough observed serum concentration (Ctrough) of INBRX-106
Tidsramme: ~2 years

Trough observed serum concentration (Ctrough) of INBRX-106 as a single agent and in combination with pembrolizumab with or without chemotherapy will be determined.

~2 years
Time to Cmax (Tmax) of INBRX-106
Tidsramme: ~2 years

Time to Cmax (Tmax) of INBRX-106 as a single agent and in combination with pembrolizumab with or without chemotherapy will be determined.

~2 years
Immunogenicity of INBRX-106
Tidsramme: ~2 years

Frequency of anti-drug antibodies (ADA) against INBRX-106 as a single agent and in combination with pembrolizumab with or without chemotherapy will be determined.

~2 years

Andre resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Anti-tumor activity of INBRX-106 as single agent and in combination with pembrolizumab with or without chemotherapy
Tidsramme: ~2 years

Tumor response will be determined by the revised Response Evaluation Criteria in Solid Tumors version 1.1 (RECISTv1.1).

~2 years
Anti-tumor activity of INBRX-106 as single agent and in combination with pembrolizumab with or without chemotherapy
Tidsramme: ~2 years

Tumor response will be determined by Response Evaluation Criteria in Solid Tumors (RECIST v1.1).

~2 years

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Samarbeidspartnere

Etterforskere

  • Studieleder: Clinical Lead, Inhibrx Biosciences, Inc

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

10. desember 2019

Primær fullføring (Antatt)

1. juli 2033

Studiet fullført (Antatt)

1. juli 2033

Datoer for studieregistrering

Først innsendt

11. desember 2019

Først innsendt som oppfylte QC-kriteriene

11. desember 2019

Først lagt ut (Faktiske)

13. desember 2019

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

6. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

4. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Ytterligere relevante MeSH-vilkår

Andre studie-ID-numre

  • Ph 1 Ph 2 INBRX-106
  • KEYNOTE A99 and MK-3475-A99 (Annen identifikator: Merck Sharp & Dohme LLC)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere